3692 — Hansoh Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$192.43bn
- HK$153.55bn
- CNY15.03bn
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
Brief: Hansoh Pharmaceutical Announces Strategic Collaboration And License Agreement With Roche
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major drugmakers turn to China for licensing deals
Brief: Hansoh Pharmaceutical Says EMA Starts Reviewing Marketing Authorization Application For Aumolertinib
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major drugmakers turn to China for licensing deals
Factbox: US drugmakers turn to China for licensing deals
Brief: Hansoh Pharmaceutical Says License Application Of Osteosarcoma Injection Accepted By NMPA
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Hansoh Pharmaceutical Says Risvutatug Rezetecan Included In NMPA Priority Review
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Hansoh rises on positive clinical trial results for plaque psoriasis drug
Primary Endpoints In Phase III Plaque Psoriasis Trial
Brief: Hansoh Pharmaceutical Says HS-20197 For Injection Receives Clinical Trial Approval From NMPA Of China